Afinitor

Type: Product
Name: Afinitor
First reported Sep 17 2014 - Updated Sep 18 2014 - 4 reports

Novartis to present cancer drug data at ESMO 2014

:16 in Pharmaceutical Company Product News Novartis has announced that it will be attending the forthcoming 2014 European Society for Medical Oncology (ESMO) congress, where it will share data on its latest cancer drug developments. Taking place in Madrid ... [Published Zenopa - Sep 17 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

TRIM44 Amplification in Esophagogastric, Breast Tumors May Be Marker for mTOR Inhibitor Therapy

By Matthew StengerSeptember 15, 2014, Volume 5, Issue 15TRIM44 family overexpression is associated with carcinogenesis, and TRIM44 has been identified as a prognostic gene. In a study reported in Journal of the National Cancer Institute , Ong and colleagues ... [Published The ASCO Post - Sep 15 2014]
First reported Sep 07 2014 - Updated Sep 07 2014 - 1 reports

Guiding Treatment of Advanced Breast Cancer Using Subtypes

Information contained on this page is provided by NewsUSA, an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith.( NewsUSA ) - For patients with breast cancer, knowing whether ... [Published WBAY Green Bay - Sep 07 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Blockbusters Differentiate Novartis

Novartis reported excellent Phase III data for its heart failure drug LCZ696, leading us to increase our ADR fair value estimate to $91 per share (CHF 83 for the local share) from $83 (CHF 73). In the 8,000-plus patient study, the drug reduced mortality ... [Published Morningstar.com - Sep 05 2014]
Entities: Novartis AG, Drugs, Patent
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

New Treatment Guidelines for Advanced Breast Cancer

Panel addresses HER2-negative diseaseA leading group of oncologists has released updated guidelines for the treatment of the major form of advanced breast cancer.Human epidermal growth factor receptor 2 (HER2)-negative breast tumors include cancers that ... [Published PT Community - Sep 03 2014]
First reported Aug 30 2014 - Updated Aug 30 2014 - 3 reports

Novartis fails to report side effects, fatality

6:52 pm, August 30, 2014 Jiji PressNovartis Pharma K.K. said it has failed to report to the health ministry at least 2,579 cases of serious side effects, including a fatality, from its drugs for leukemia and other diseases even though its employees ... [Published PharmaGossip - Aug 30 2014]
First reported Aug 24 2014 - Updated Aug 24 2014 - 1 reports

Using subtypes to guide treatment of advanced breast cancer

For patients with breast cancer, knowing whether the diagnosis is early stage or advanced is needed to help treat the disease.Vice-President and Chief Medical Officer for Georgia Cancer Specialists, Cheryl Jones, MD, has experience in treating patients ... [Published New Sarawak Tribune - Aug 24 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Using Subtypes to Guide Treatment of Advanced Breast Cancer

(NewsUSA) - For patients with breast cancer, knowing whether the diagnosis is early stage or advanced is needed to help treat the disease.Afinitor can cause serious side effects, including lung or breathing problems, infections, and kidney failure, which ... [Published Sonoma West Times and News - Aug 14 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Using Subtypes to Guide Treatment of Advanced Breast Cancer

12 Aug 2014 11:43 ( NewsUSA ) - For patients with breast cancer, knowing whether the diagnosis is early stage or advanced is needed to help treat the disease.Vice-President and Chief Medical Officer for Georgia Cancer Specialists, Cheryl Jones, MD, ... [Published Palos Regional - Aug 12 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 2 reports

The Texas Medical Board vs. Stanislaw Burzynski, Round Infinity [Respectful Insolence]

There’s a point I feel that I have have to make briefly as I begin this post. Basically, this might look familiar, but given that I was at TAM Wednesday through Sunday, I didn’t have time to produce two separate posts, and this is important enough ... [Published ScienceBlogs : Combined Feed - Jul 14 2014]
First reported Jun 12 2014 - Updated Jun 13 2014 - 1 reports

Human medicines European public assessment report (EPAR): Afinitor, everolimus, Revision: 12, Authorised

Quotes

...Dr Alessandro Riva, global head of Novartis oncology development and medical affairs business, said: "Our clinical programme has led to the development of precise therapies for patients with the specific genetic profile targeted by these treatments, enabling us to make a difference for people living with these diseases." This comes after the firm presented data on its ophthalmology portfolio, including Lucentis and Jetrea, at the EURETINA congress in London last week...
"At ESMO 2014 we will present new data on key compounds that demonstrate the breadth of the biological markers we target" said Alessandro Riva, MD, Global Head, Novartis Oncology Development and Medical Affairs...
...Though no specific data was released, the press release notes that the study "met its primary endpoint [of] delivering a statistically significant increase in progression-free survival."
"The number of people who are overweight or obese in England is rising. Obesity not only damages their health but dealing with the long-term consequences of obesity costs the NHS around £5.1 billion each year."

More Content

All (37) | News (30) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Novartis to present cancer drug data at ESMO 2014 [Published Zenopa - Sep 17 2014]
Novartis presents oncology research advances wi... [Published ACN Newswire - Sep 17 2014]
Novartis presents oncology research advances wi... [Published InfoStor - Sep 17 2014]
Novartis presents oncology research advances wi... [Published Nasdaq - Sep 17 2014]
TRIM44 Amplification in Esophagogastric, Breast... [Published The ASCO Post - Sep 15 2014]
The New Rules of Pharma Marketing [Published Insead Knowledge - Sep 11 2014]
Guiding Treatment of Advanced Breast Cancer Usi... [Published WBAY Green Bay - Sep 07 2014]
Blockbusters Differentiate Novartis [Published Morningstar.com - Sep 05 2014]
New Treatment Guidelines for Advanced Breast Ca... [Published PT Community - Sep 03 2014]
Exelixis, Inc.'s Not So Excellent Prostate Canc... [Published Motley Fool Discussion Boards - Sep 02 2014]
Novartis fails to report side effects, fatality [Published PharmaGossip - Aug 30 2014]
Novartis fails to report side effects, fatality [Published The Japan News - Aug 30 2014]
Novartis Pharma fails to report over 2,500 seri... [Published Japan Times - Aug 30 2014]
Transforming Cancer Care and the Role of Paymen... [Published Brookings Latest From Brookings - Aug 26 2014]
Using subtypes to guide treatment of advanced b... [Published New Sarawak Tribune - Aug 24 2014]
Neuroendocrine Carcinoma Market - Global Indust... [Published MyNewsDesk - Aug 21 2014]
Bionomics 2013/2014 Preliminary Final Results [Published Noodls - Aug 19 2014]
Using Subtypes to Guide Treatment of Advanced B... [Published Sonoma West Times and News - Aug 14 2014]
Using Subtypes to Guide Treatment of Advanced B... [Published Palos Regional - Aug 12 2014]
Novartis net up by 3% to $3,283 million in Q2 [Published PharmaBiz - Jul 18 2014]
The Texas Medical Board vs. Stanislaw Burzynski... [Published ScienceBlogs : Combined Feed - Jul 14 2014]
The Texas Medical Board vs. Stanislaw Burzynski... [Published Science-Based Medicine - Jul 14 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jun 12 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Jun 11 2014]
Obesity among British girls highest in Western ... [Published Telegraph - May 29 2014]
Novartis reports healthy profit [Published BioPortfolio - Apr 25 2014]
Novartis net up by 24% in Q1 to $2,968 million [Published PharmaBiz - Apr 25 2014]
Three New Personalized Medicines for Breast Can... [Published PRWeb - Apr 03 2014]
Patent expiration, stagnant R&D spend seriously... [Published PharmaBiz - Mar 28 2014]
What is Nice? Drugs body Q [Published Telegraph - Mar 27 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Novartis fails to report side effects, fatality [Published PharmaGossip - Aug 30 2014]
6:52 pm, August 30, 2014 Jiji PressNovartis Pharma K.K. said it has failed to report to the health ministry at least 2,579 cases of serious side effects, including a fatality, from its drugs for leukemia and other diseases even though its employees ...
Transforming Cancer Care and the Role of Paymen... [Published Brookings Latest From Brookings - Aug 26 2014]
Living With Cancer: Vicky's Story Vicky Bolton is a 58 year-old medical legal coordinator who lives in Albuquerque, New Mexico. A widower of 20 years, Vicki has three children and nine grandchildren. She is also a Stage 4 adenocarcinoma lung cancer ...
The Texas Medical Board vs. Stanislaw Burzynski... [Published ScienceBlogs : Combined Feed - Jul 14 2014]
There’s a point I feel that I have have to make briefly as I begin this post. Basically, this might look familiar, but given that I was at TAM Wednesday through Sunday, I didn’t have time to produce two separate posts, and this is important enough ...
The Texas Medical Board vs. Stanislaw Burzynski... [Published Science-Based Medicine - Jul 14 2014]
As I begin this post, I’m no a miserably crowded, hot, stinky flight winging my way home from TAM . This puts me in the perfect mood to write about my bête noire to conquer all bêtes noires, namely Stanislaw Burzynski, the Polish expat doctor who ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jun 12 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.